Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

22 juil. 2026 07h00 HE | Source: Healx

Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma

Cambridge, UK – 22 July, 2026 – Healx, an AI-powered, clinical-stage biotech company dedicated to rare diseases, today announced that the first patient has been dosed in its Phase 1/2 dose-escalation...
22 juil. 2026 02h00 HE | Source: Healx

Healx Announces First Patient Dosed in Phase 1/2 Trial to Evaluate the Effect of HLX-4310 on Metastatic Recurrence and Progression in Sarcomas with a Focus on Osteosarcoma

Cambridge, UK – 22 July, 2026 – Healx, an AI-powered, clinical-stage biotech company dedicated to rare diseases, today announced that the first patient has been dosed in its Phase 1/2 dose-escalation...